Compare YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF vs Repligen Corporation Common Stock — how do they compare? YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $37.9 (market cap $29.26M), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 380.7× YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF for 64 Days and Repligen Corporation Common Stock for 0 Days on average.
| QDTY | RGEN | |
|---|---|---|
Market Cap | $29.26M | $11.14B |
Volume | 13,576 | 1,259,263 |
Sector | Income / Options Overlay | Health |
52-Week High | $46.71 | $194.57 |
52-Week Low | $36.57 | $102.87 |
Typical Hold Time | 64 Days | 0 Days |
Enterprise Value | — | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QDTY trades at $38.94, down 0.36% with bearish technical signals from moving averages. The ETF maintains a consistent weekly dividend distribution strategy, with recent payments ranging from $0.19 to $0.30 per share. Technical indicators show mixed signals with RSI in neutral territory while ADX suggests weakening trend strength. The stock faces resistance at $40 with support clustered around $39.
The outlook remains cautious given bearish technical momentum and concentrated support levels. Dividend consistency provides income appeal, but technical weakness and tight trading range near current levels suggest limited near-term upside potential. Key risks include market volatility impact on covered call strategies and dependency on Nasdaq 100 performance.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
